SecBot SecBot
8-K ·Filed Feb 26, 2026

AVNS

AVANOS MEDICAL, INC.
NEUTRAL
Impact 5/10
Horizonweeks Processed8mo ago SEC0001606498-26-000007
8-K material event: Items 1.01
Actionable Insight • Neutral

Monitor the performance of the new board members and assess whether the governance changes lead to strategic shifts or improved performance in future earnings reports.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$14.49
T+0 close · Feb 26, 2026 · via day close
Latest settled
+70.46%
T+60 · $24.70
Vs SPY
+62.71%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $14.49entry
  2. T+1 · 9mo ago −2.69%α −2.24% · $14.10
  3. T+5 · 9mo ago −4.83%α −3.70% · $13.79
  4. T+20 · 8mo ago −4.42%α +1.99% · $13.85
  5. T+60 · 6mo ago +70.46%α +62.71% · $24.70
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Avanos Medical has entered into an agreement with activist investor Bradley L. Radoff to add two new independent directors, James Cunniff and William Burke, to its board in exchange for Radoff withdrawing his director nomination and agreeing to a standstill provision. This resolves a potential proxy contest and brings new leadership with complementary medical technology and financial expertise.

Key Facts

  • Avanos agreed to nominate James Cunniff and William Burke to its Board of Directors
  • Bradley L. Radoff withdrew his director nomination and agreed to a standstill provision
  • Radoff Parties beneficially own 830,100 shares (approximately 1.7%) of Avanos common stock
  • The agreement includes mutual non-disparagement clauses and voting commitments
  • Avanos will reimburse Radoff Parties for expenses up to $150,000

Financial Impact

Minimal direct financial impact, with Avanos reimbursing up to $150,000 in expenses

expensesgovernance

Risk Factors

  • Potential for future disagreements between management and the new board members
  • The standstill agreement expires in early 2027, potentially leading to renewed activist pressure

Market Snapshot

Exchange
NYSE

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001606498-26-000007
Document: avns-20260225.htm0001606498-26-000007
Document: avnsform8k_02262026xex991.htm0001606498-26-000007
Document: 0001606498-26-000007-index-headers.html0001606498-26-000007
Document: 0001606498-26-000007-index.html0001606498-26-000007
Document: 0001606498-26-000007.txt0001606498-26-000007

Track record

7 reports on AVNS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +1.13% at T+60 after the Apr 23, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Jul 27, 202616w ago 25-NSE Neutral 5/10 Entry $24.99 No price data
  2. Jul 2, 202619w ago 8-K / DEFA14A Bullish 7/10 Entry $24.93 to $24.94 ▲ +0.04% −0.89% vs SPY
  3. Jun 10, 202622w ago DEFM14A Bullish 8/10 Entry $24.98 to $24.87 ▼ −0.44% −0.87% vs SPY
  4. May 5, 202627w ago DEFA14A Neutral 5/10 Entry $24.72 to $24.73 ▲ +0.04% −1.09% vs SPY
  5. Apr 23, 202629w ago DEFA14A Bullish 8/10 Entry $24.71 to $24.65 ▼ −0.24% −1.72% vs SPY
  6. Apr 14, 202630w ago DEFA14A Neutral 4/10 Entry $24.63 to $24.64 ▲ +0.04% −1.35% vs SPY
  7. Feb 26, 202637w ago 8-K Neutral 5/10 Viewing Entry $14.49 to $13.79 ▼ −4.83% −3.70% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens in 6h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026